# Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma

> **NCT00323570** · PHASE3 · WITHDRAWN · sponsor: **Novo Nordisk A/S**

## Conditions studied

- Acquired Bleeding Disorder
- Trauma

## Interventions

- **DRUG:** activated recombinant human factor VII

## Key facts

- **NCT ID:** NCT00323570
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-05
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00323570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00323570, "Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00323570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*